Exchange: NASDAQ·Updated 07:30 PM EST

QURE News

News
all
press releases
uniQure N.V. $QURE Stake Cut by Aberdeen Group plc
Aberdeen Group plc cut its stake in uniQure N.V. (NASDAQ:QURE - Free Report) by 99.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,425 shares of the biotechnology company's stock after selling 2,834,692 shares during t...
MarketBeat
uniQure N.V. $QURE Stake Cut by Aberdeen Group plc
Aberdeen Group plc cut its stake in uniQure N.V. (NASDAQ:QURE - Free Report) by 99.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,425 shares of the biotechnology company's stock after selling 2,834,692 shares during t...
MarketBeat
More News
uniQure N.V. (NASDAQ:QURE - Free Report) - Equities research analysts at HC Wainwright increased their FY2026 EPS estimates for shares of uniQure in a research note issued on Wednesday, November 18th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will post earnings p...
MarketBeat
HC Wainwright reduced their price target on shares of uniQure from $80.00 to $65.00 and set a "buy" rating on the stock in a research report on Wednesday...
MarketBeat
Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) have been given an average rating of "Moderate Buy" by the sixteen analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recomm...
MarketBeat
uniQure shares rally 17.5% as FDA grants Priority Review to its Huntington's disease gene therapy, but it remains to be seen if clinical and regulatory progress can sustain momentum.
Zacks
uniQure (QURE) delivered earnings and revenue surprises of -4.76% and -27.33%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
Zacks
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. (uniQure or the Company) (NASDAQ: QURE) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws or other unlawful business...
Business Wire
QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.
Zacks
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)PR NewswireNEW YORK, Sept. 29, 2026uniQure's four-year AMT-130 Huntington's disease benefit...
PR Newswire

Advertisement|Remove ads.